← Back to search
JUSTUS-LIEBIG-UNIVERSITÄT GIESSEN
GIESSEN, 35390
UnclaimedClaim this profile (free)
Subcontracting experience
2 records from government sources. Past participation is not evidence of current teaming interest.
| Role | Agency | Description | Vehicle | Obligated | Action date | Period |
|---|---|---|---|---|---|---|
| Subcontractor | Department of Health and Human Services | OUR PROJECT AIMS TO DEVELOP A NEW DRUG EFFECTIVE AGAINST MULTIDRUG-RESISTANT (MDR) GRAM-NEGATIVE BACTERIA. OUR EARLY LEAD COMPOUNDS ARE DERIVED FROM A NATURAL PRODUCT AND REPRESENT A NOVEL CLASS OF COMPOUNDS FEATURING A NOVEL MODE OF ACTION. THE AGENTS ARREST THE FUNCTION OF BAMA, AN ESSENTIAL COMPONENT FOR BACTERIAL SURVIVAL, WHICH NO CURRENT DRUGS TARGET. BAMA, IS AN ESSENTIAL COMPONENT OF THE ÃƑŸ-BARREL ASSEMBLY MACHINERY (BAM), LOCATED IN THE OUTER MEMBRANE (OM) OF GRAM-NEGATIVE BACTERIA; THE TARGET IS NOT PRESENT IN HUMANS (SPECIFIC). BAMA FOLDS AND INTEGRATES OM-PROTEINS INTO THE OM; INHIBITION LEADS TO OM BLEBBING AND ULTIMATELY CELL LYSIS (ESSENTIAL). SINCE BAMA HAS NOT BEEN TARGETED BY ANY EXISTING DRUGS, BACTERIA HAVE NOT DEVELOPED TARGET-BASED RESISTANCE. HENCE, OUR PROGRAM CAN BE REGARDED AS THE FOUNDATION FOR THE DEVELOPMENT OF A FIRST IN CLASS BAMA INHIBITOR. WE WILL FOCUS ON TREATING HOSPITAL-ACQUIRED INFECTIONS SUCH AS PNEUMONIA CAUSED BY MDR BACTERIA. THESE INFECTIONS ARE CLASSIFIED AS A €œCRITICAL PRIORITY€Ͽ½ BY THE WORLD HEALTH ORGANIZATION (WHO) DUE TO THEIR SEVERITY AND LIMITED TREATMENT OPTIONS. 4500005270 Parent award context Parent award agency: Department of Health and Human Services · Office of Assistant Secretary for Preparedness and Response Parent award NAICS: 541714 Parent award performance state: MA Parent award description: CARB-X GLOBAL ANTIBACTERIAL ACCELERATOR OTA View parent award on USAspending | — | -$61,028 | Feb 28, 2025 | — – — |
| Subcontractor | Department of Health and Human Services | OUR PROJECT AIMS TO DEVELOP A NEW DRUG EFFECTIVE AGAINST MULTIDRUG-RESISTANT (MDR) GRAM-NEGATIVE BACTERIA. OUR EARLY LEAD COMPOUNDS ARE DERIVED FROM A NATURAL PRODUCT AND REPRESENT A NOVEL CLASS OF COMPOUNDS FEATURING A NOVEL MODE OF ACTION. THE AGENTS ARREST THE FUNCTION OF BAMA, AN ESSENTIAL COMPONENT FOR BACTERIAL SURVIVAL, WHICH NO CURRENT DRUGS TARGET. BAMA, IS AN ESSENTIAL COMPONENT OF THE ÃƑŸ-BARREL ASSEMBLY MACHINERY (BAM), LOCATED IN THE OUTER MEMBRANE (OM) OF GRAM-NEGATIVE BACTERIA; THE TARGET IS NOT PRESENT IN HUMANS (SPECIFIC). BAMA FOLDS AND INTEGRATES OM-PROTEINS INTO THE OM; INHIBITION LEADS TO OM BLEBBING AND ULTIMATELY CELL LYSIS (ESSENTIAL). SINCE BAMA HAS NOT BEEN TARGETED BY ANY EXISTING DRUGS, BACTERIA HAVE NOT DEVELOPED TARGET-BASED RESISTANCE. HENCE, OUR PROGRAM CAN BE REGARDED AS THE FOUNDATION FOR THE DEVELOPMENT OF A FIRST IN CLASS BAMA INHIBITOR. WE WILL FOCUS ON TREATING HOSPITAL-ACQUIRED INFECTIONS SUCH AS PNEUMONIA CAUSED BY MDR BACTERIA. THESE INFECTIONS ARE CLASSIFIED AS A €œCRITICAL PRIORITY€Ͽ½ BY THE WORLD HEALTH ORGANIZATION (WHO) DUE TO THEIR SEVERITY AND LIMITED TREATMENT OPTIONS. 4500005270 Parent award context Parent award agency: Department of Health and Human Services · Office of Assistant Secretary for Preparedness and Response Parent award NAICS: 541714 Parent award performance state: MA Parent award description: CARB-X GLOBAL ANTIBACTERIAL ACCELERATOR OTA View parent award on USAspending | — | $335,651 | Dec 18, 2024 | — – — |
Contract vehicles are shown only when present in the source record. Linked award numbers and vehicles open the authoritative record on USAspending.gov.
Government-sourced data comes from SAM.gov, SBA and USAspending.gov and is attributed to its source. Items marked company-reported were provided by the company and are verified by FedSub only where labeled. FedSub is a private company and is not affiliated with SBA, GSA/SAM.gov, or any government agency.